Beyond chemoresistant melanoma and platinum-resistant ovarian cancer, mebendazole (MBZ) exhibits preclinical and/or clinical activity across a wide range of solid and hematologic malignancies:
1. Central Nervous System (Brain) Tumors
Glioblastoma Multiforme (GBM) & High-Grade Gliomas: Preclinical models (GL261, 060919) show MBZ inhibits tubulin polymerization, crosses the blood-brain barrier, and significantly extends survival compared to standard treatments. It is also being evaluated in Phase 1 clinical trials for adult and pediatric high-grade gliomas.
Medulloblastoma: Preclinical models (including DAOY and D425) demonstrate that MBZ blocks Sonic Hedgehog (SHH) signaling and c-MYC amplification, reducing tumor angiogenesis and prolonging survival.
Malignant Meningioma: MBZ decreases clonogenic survival, induces apoptosis, and acts as a powerful radiosensitizer in intracranial meningioma models.
2. Gastrointestinal Malignancies
Colorectal Cancer: MBZ inhibits proliferation in 80% of tested NCI-60 colon cancer cell lines (HT29, SW480, HCT116, RKO) and drastically reduces tumor initiation in ApcMin/+ mouse models. A clinical case report documented near-complete remission of lung/lymph node metastases and partial liver remission in refractory metastatic colon cancer.
Gastric Cancer & Malignant Ascites: MBZ suppresses cell migration/invasion (ACP-02, AGP-01), downregulates c-MYC, inhibits matrix metalloproteinases (MMP-2), and decreases multidrug resistance transporters (P-gp and MRP1).
Pancreatic & Cholangiocarcinoma: MBZ disrupts stromal desmoplasia in pancreatic cancer models and inhibits tumor growth in cholangiocarcinoma (bile duct cancer) and hepatocellular carcinoma.
3. Gynecologic, Urologic, & Breast Cancers
Breast Cancer: Across triple-negative (TNBC), ER+, and HER2+ breast cancers, MBZ suppresses hypoxia-inducible factors (HIF-1α and HIF-2α), depletes ALDH1+ cancer stem cells, and significantly reduces distant metastases to the lungs and liver.
Prostate Cancer: In androgen-dependent (LNCaP) and castration-resistant (DU145, PC3) lines, MBZ reverses epithelial-to-mesenchymal transition (EMT), downregulates taxane-resistance isoforms (TUBB1, TUBB3), and synergizes with anti-androgens (flutamide) or chemotherapy (docetaxel).
4. Respiratory, Head, and Neck Cancers
Non-Small Cell Lung Cancer (NSCLC): MBZ depolymerizes tubulin, induces mitotic arrest, causes post-translational p53 stabilization, and prevents metastatic lung colony formation in vivo by up to 80%.
Head & Neck Squamous Cell Carcinoma (HNSCC) & Oral Cancers: MBZ promotes tumor cell differentiation (extensive keratinization) and enhances cisplatin sensitivity.
5. Skin, Endocrine, & Hematologic Malignancies
Adrenocortical & Thyroid Cancers: MBZ induces mitochondrial apoptosis in adrenocortical carcinoma (H295R, SW-13) with clinical case evidence of 19-month metastatic disease control. It also blocks growth and lung metastasis in advanced thyroid cancer models.
Leukemia & Multiple Myeloma: MBZ acts as a differentiation therapy in Acute Myeloid Leukemia (AML) by inducing proteasomal degradation of c-MYB, and inhibits the USP5/c-Maf axis in multiple myeloma.
Osteosarcoma: MBZ demonstrates selective cytotoxicity in human and canine osteosarcoma models at clinically achievable oral doses.
Mebendazole Cancer Mechanisms
Mebendazole (MBZ) achieves selective cytotoxicity in chemoresistant cancer cells through a combination of targeted apoptotic triggers, suppression of pro-survival signaling networks, disruption of hypoxia-driven resistance mechanisms, and inhibition of drug efflux transporters:
1. Differential Bcl-2 Phosphorylation and Inactivation
Selective Apoptotic Triggering: While MBZ depolymerizes microtubules in both normal and malignant cells by binding to the colchicine-binding site, chemoresistant cancer cells exhibit a distinct cellular response to this damage.
Bcl-2 Phosphorylation at Ser70: In chemoresistant melanoma lines (such as M-14 and SK-Mel-19), MBZ rapidly induces phosphorylation of the anti-apoptotic protein Bcl-2 at Ser70. Normal melanocytes do not undergo Bcl-2 phosphorylation under the same conditions.
Bax Disinhibition: Phosphorylation inactivates Bcl-2, reducing its interaction with pro-apoptotic Bax by 46% to 64%. Unbound Bax is liberated to form homodimers that activate the intrinsic mitochondrial apoptotic cascade (cleavage of caspase-9, caspase-7, caspase-3, and PARP), followed by extrinsic pathway activation (caspase-8).
Bcl-2 Dependance: Knockdown of Bcl-2 via siRNA in initially insensitive melanocytes sensitizes them to MBZ cytotoxicity (reducing IC50 by 26-fold), establishing Bcl-2 state as a primary mediator of MBZ’s selective toxicity.
2. Inhibition of Multiple Pro-Survival Signaling Pathways
Platinum Resistance Overcome: In stable cisplatin-resistant ovarian cancer cell lines (OVCAR8CR and SKOV3CR), MBZ markedly suppresses key transcriptional pathways driving cell survival and proliferation, specifically ELK/SRF, NF-κB, MYC/MAX, E2F/DP1, TGF/SMAD, and AP1, while upregulating pro-apoptotic genes BAX and CASP3.
Reversal of Epithelial-to-Mesenchymal Transition (EMT): In chemoresistant prostate cancer cell lines (DU145 and PC3), MBZ increases the BAX/BCL2 mRNA ratio, upregulates E-cadherin, and downregulates aggressive, taxane-resistance-associated β-tubulin isoforms (TUBB1 and TUBB3).
XIAP Downregulation: MBZ induces time-dependent degradation of X-linked inhibitor of apoptosis (XIAP), removing a key block on caspases 3, 7, and 9 in resistant cells.
3. Suppression of Hypoxia-Inducible Factors (HIFs)
Tumor core hypoxia is a primary driver of the chemoresistant phenotype. MBZ disrupts the protein induction and transcriptional activity of HIF-1α, HIF-2α, and HIF-1β under low-oxygen conditions.
MBZ treatment abrogates the expression of HIF target genes (such as CA9, NDRG1, EPO, and BNIP3), effectively blocking hypoxia-induced chemoresistance and metastatic potential in solid tumors.
4. Multi-Kinase Inhibition and Efflux Pump Suppression
Kinase Targeting: MBZ acts as a broad multi-kinase inhibitor, targeting oncogenic drivers including TNIK, BRAF (both wild-type and V600E), MEK, VEGFR2, BCR-ABL, and MAPK14 in nanomolar to low-micromolar ranges.
Downregulation of Drug Transporters: MBZ significantly decreases the expression of multidrug resistance transporters, including P-glycoprotein 1 (P-gp) and MRP1, thereby inhibiting therapeutic drug efflux and restoring intracellular sensitivity in chemoresistant cells.
References
Chai, J.-Y., Cho, S.-Y., Sohn, W.-M., & Hong, S.-T. (2021). Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. The Korean Journal of Parasitology, 59(3), 189–225. https://doi.org/10.3347/kjp.2021.59.3.189
Doudican, N., Rodriguez, A., Osman, I., & Orlow, S. J. (2008). Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Molecular Cancer Research, 6(8), 1308–1315. https://doi.org/10.1158/1541-7786.MCR-07-2159
Fattahi, M. R., Taheri, D., Inanloo, S. H., Mirzaei, A., Ghajar, H. A., Reis, L. O., & Aghamir, S. M. K. (2026). Effects of mebendazole and flutamide combination in prostate cancer cell lines: A comprehensive in vitro analysis. Cellular Physiology and Biochemistry, 60, 458–472. https://doi.org/10.33594/000000883
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., Bresciani, R., Magrini, S. M., & Buglione, M. (2019). Mebendazole as a candidate for drug repurposing in oncology: An extensive review of current literature. Cancers, 11(9), Article 1284. https://doi.org/10.3390/cancers11091284
Huang, L., Zhao, L., Zhang, J., He, F., Wang, H., Liu, Q., Shi, D., Ni, N., Wagstaff, W., Chen, C., Reid, R. R., Haydon, R. C., Luu, H. H., Shen, L., He, T.-C., & Tang, L. (2021). Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging, 13(16), Article 203232. https://doi.org/10.18632/aging.203232
Joe, N. S., Wang, Y., Oza, H. H., Godet, I., Milki, N., Riggins, G. J., & Gilkes, D. M. (2023). Mebendazole treatment disrupts the transcriptional activity of hypoxia-inducible factors 1 and 2 in breast cancer cells. Cancers, 15(4), Article 1330. https://doi.org/10.3390/cancers15041330
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013). Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. Journal of Cancer Research and Clinical Oncology, 139(12), 2133–2140. https://doi.org/10.1007/s00432-013-1539-5
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2014). Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent. ecancermedicalscience, 8, Article 443. https://doi.org/10.3392/ecancer.2014.443